CD39+ cells also showed a less diverse TCR repertoire than CD39− cells, suggesting clonal expansion of effector cells by stimulation with tumour‐associated neoantigens in small cohorts of NSCLC and CRC patients [50]. This evidence concerns the gene ENTPD1 and colorectal carcinoma.